3.6  0.27 (8.11%)		08-13 16:00
Open: 3.31 High: 3.6 Volume: 7,798		Pre. Close: 3.33 Low: 3.27 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	4.49	1-year :	5.04
Resists	First :	3.85	Second :	4.32
Pivot price	3.44
Supports	First :	3.08	Second :	2.57
MAs	MA(5) :	3.33	MA(20) :	3.54
	MA(100) :	3.31	MA(250) :	6.72
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	41.1	D(3) :	25.1
RSI	RSI(14): 52.2
52-week	High :	28.03	Low :	1.83

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NCEL ] has closed below upper band by 23.2%. Bollinger Bands are 47% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.61 - 3.62	3.62 - 3.64
Low:	3.34 - 3.36	3.36 - 3.38
Close:	3.57 - 3.6	3.6 - 3.63

NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

Fri, 31 Jul 2026
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative

Fri, 24 Jul 2026
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView

Mon, 04 May 2026
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView

Thu, 30 Apr 2026
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative

Mon, 09 Mar 2026
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PR Newswire

Thu, 29 Jan 2026
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	5 (M)
Shares Float	3 (M)
Held by Insiders	68 (%)
Held by Institutions	1.1 (%)
Shares Short	57 (K)
Shares Short P.Month	60 (K)

EPS	-2.17
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.5
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-26 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.47
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-1.67
PEG Ratio	0
Price to Book value	2.38
Price to Sales	0
Price to Cash Flow	-7

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.